Utilising aquaporins could be the key to repairing corneal defects
New evidence suggests that aquaporin 5 (Aqp5) induction promotes corneal epithelial regeneration, which could lead to possible therapies.
List view / Grid view
New evidence suggests that aquaporin 5 (Aqp5) induction promotes corneal epithelial regeneration, which could lead to possible therapies.
Dubbed 'Zaki syndrome', the condition affects prenatal development of several organs and was identified using whole genome sequencing.
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
Lipophosphonoxins may represent the next generation of antibiotics and can be delivered using a new type of dressing for skin wounds.
An interview with Dr Arun Srivastava about his research into safe and effective AAV vectors that do not prompt a reaction from the immune system.
The European Medicines Agency is promoting three principles – replace, reduce and refine – to reduce animal testing in medicine development.
Save time by measuring 48 immune factors, generating more than 1,800 data points from a single plate, with a small sample volume.
A CRISPR screening tool identified a new target for acute myeloid leukaemia with fewer side effects than current approaches.
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
Limiting neuroinflammation was shown to be a promising approach to treat neurological diseases such as stroke and spinal cord injury in mice.
The over-expression of a growth factor receptor resulted in hypomyelination, leading to diseases such as multiple sclerosis in mouse models.
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…